CIK 0001980845
- Emerging growth company
enGene Therapeutics Inc.
Sign in to watch- Ticker
- ENGN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Oct 31
- Incorporated
- Canada (Federal Level)
- Entity type
- Operating
- Phone
- +1 514-332-4888
- Business address
- 4868 RUE LEVY, SUITE 220, SAINT-LAURENT, Quebec, Canada
- Former names
- enGene Holdings Inc.
Securities
- ENGN Common Stock Nasdaq
- ENGNW Warrants Nasdaq
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Exercise or conversion Director acquired 120 shares (option exercise)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale 10% owner sold 52,529 shares at an average $15.00 ($787,981)
- 4 Derivatives Options or other derivatives
- 4 Exercise or conversion Chief Technology Officer acquired 52,940 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 4 Grant or award Director acquired 800,000 shares (grant or award)
- 4 Grant or award 10% owner acquired 800,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
Page 4 of 5 · 98 filings